Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kazuhiro Ohkouchi is active.

Publication


Featured researches published by Kazuhiro Ohkouchi.


Journal of Drug Targeting | 1994

Membrane Modification by Negatively Charged Stearyl-Polyoxyethylene Derivatives for Thermosensitive Liposomes: Reduced Liposomal Aggregation and Avoidance of Reticuloendothelial System Uptake

Katsumiiga; Kazuhiro Ohkouchi; Yasuaki Ogawa; Hajime Toguchi

In order to avoid reticuloendothelial system (RES) uptake and prolong systemic circulation of cisplatin (CDDP)-encapsulating thermosensitive liposomes, stearylpolyoxyethylene (POE) derivatives [SnC, stearyl-O-(CH2CH2O)n-CH2COONa] were incorporated as membrane modifiers into lipid bilayers composed of dipalmitoylphosphatidylcholine (DPPC) and distearoylphosphatidylcholine (DSPC). The incorporation of S2C, S5C, S10C or S15C [lipid/SnC = 10/2 (w/w)] greatly reduced liposomal aggregation without impairing liposomal stability. After being intravenously administered to rats, the liposomes remained longer in the systemic circulation and showed lower RES levels than the control liposomes. When incorporated into liposomes [DPPC/DSPC = 7/3 (w/w)], S10C provided the greatest increase in systemic circulation time and the RES-avoiding activity among the modifiers tested. The systemic elimination rate (the ratio of the percent of the dose systemically eliminated to the AUC of the liposome level) for this type of liposome was 0.24/hr, about one fourth the rate for the control liposomes, and the RES uptake rate (the ratio of the percent of the dose taken up by the RES to the AUC) was 0.04/hr, one seventh the rate for the control liposomes. The RES uptake rate for S10C 7/3-liposomes was similar to the rate reported for GM1 liposomes, although the systemic elimination rate was double that for the GM1 liposomes. The obtained RES avoidance activity can be attributed to decreased liposomal aggregation and increased surface hydrophilicity. This type of thermosensitive liposome should be more useful in hyperthermia-mediated targeted tumor drug delivery systems than the thermosensitive liposomes without the modifiers to avoid RES uptake.


Archive | 2000

Quickly disintegrating solid preparations

Kazuhiro Ohkouchi; Hiroyoshi Koyama


Archive | 2000

Rotary type powder compression molding machine

Keiji Shimada; Shuji Morimoto; Kazuhiro Ohkouchi; Naoru Hamaguchi


Archive | 2004

Process for producing coated preparation

Kazuhiro Ohkouchi; Masahiko Koike; Hiroyoshi Koyama; Naoru Hamaguchi


Archive | 1991

Liposome composition whose liposome membrane contains a polyoxyethylene derivative

Katsumi Iga; Kazuhiro Ohkouchi; Yasuaki Ogawa


Archive | 2002

Rapidly disintegratable solid preparation

Kazuhiro Ohkouchi; Hiroyoshi Koyama


Archive | 2005

PROCESO PARA PRODUCIR UNA PREPARACION RECUBIERTA

Kazuhiro Ohkouchi; Masahiko Koike; Hiroyoshi Koyama; Naoru Hamaguchi


Archive | 2004

Verfahren zur herstellung einer beschichteten zubereitung

Kazuhiro Ohkouchi; Masahiko Koike; Hiroyoshi Koyama; Naoru Hamaguchi


Archive | 2004

Procede pour realiser une preparation enrobee

Kazuhiro Ohkouchi; Masahiko Koike; Hiroyoshi Koyama; Naoru Hamaguchi


Archive | 2002

Preparation solide se desintegrant rapidement

Kazuhiro Ohkouchi; Hiroyoshi Koyama

Collaboration


Dive into the Kazuhiro Ohkouchi's collaboration.

Top Co-Authors

Avatar

Hiroyoshi Koyama

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Naoru Hamaguchi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Masahiko Koike

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Yasuaki Ogawa

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Katsumi Iga

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Hajime Toguchi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Keiji Shimada

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Shuji Morimoto

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge